Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcutis BiotherapeuticsARQT -1.36%56 Debt-to-Equity is 0.52 as of Jun. 2026, which is 13% below its 10-year median of 0.60. GuruFocus rates ARQT with a GF Score™ of 56/100 and a GF Value™ of $30.59 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 958 Biotechnology companies, Arcutis Biotherapeutics ranks worse than 75.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Arcutis Biotherapeutics's Debt-to-Equity or its related term are showing as below:
ARQT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0.6 Max: 4.39
Current: 0.52
During the past 9 years, the highest Debt-to-Equity Ratio of Arcutis Biotherapeutics was 4.39. The lowest was -0.01. And the median was 0.60.
ARQT's Debt-to-Equity is ranked worse than 75.57% of 958
companies
in the Biotechnology industry
Industry Median: 0.16
vs ARQT: 0.52
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Arcutis Biotherapeutics Debt-to-Equity Related Terms
Arcutis Biotherapeutics Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ARQT vs IDYA, NAMS, ALMS: Debt-to-Equity Comparison
For the Biotechnology subindustry, Arcutis Biotherapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcutis Biotherapeutics Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcutis Biotherapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Arcutis Biotherapeutics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcutis Biotherapeutics (ARQT) has a Debt-to-Equity of 0.52 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Arcutis Biotherapeutics and its competitors. This is 13% below median its historical median of 0.60. According to the industry distribution chart, Arcutis Biotherapeutics ranks #724 out of 958 companies in the Biotechnology industry, placing it in the top 75.6%.
Is Arcutis Biotherapeutics' Debt-to-Equity too high?
Arcutis Biotherapeutics' current Debt-to-Equity of 0.52 is 13% below median its 10-year median of 0.60. The Biotechnology industry median Debt-to-Equity is 0.16. Arcutis Biotherapeutics' value of 0.52 is 225% above this industry median. Based on the distribution chart, Arcutis Biotherapeutics ranks #724 out of 958 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arcutis Biotherapeutics has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arcutis Biotherapeutics' Debt-to-Equity compare to IDYA and NAMS?
According to the Biotechnology industry distribution chart, Arcutis Biotherapeutics ranks #724 out of 958 companies for Debt-to-Equity. This places Arcutis Biotherapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Arcutis Biotherapeutics' value of 0.52 is 225% above this benchmark. While the company's 10-year median is 0.60 vs. the industry median of 0.16, Arcutis Biotherapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arcutis Biotherapeutics's current Debt-to-Equity of 0.52 is 225% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Arcutis Biotherapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcutis Biotherapeutics's current Debt-to-Equity is 0.52, which is 13% below median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcutis Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arcutis Biotherapeutics (ARQT) is currently considered Modestly Undervalued. The stock's GF Value™ is $30.59, compared to a current price of $25.02 — trading 18.2% below its estimated fair value. The current Debt-to-Equity is 0.52, which is 13% below median its 10-year median of 0.60 and 225% above the Biotechnology industry median of 0.16. Arcutis Biotherapeutics' overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Arcutis Biotherapeutics (ARQT), the current Debt-to-Equity is 0.52 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcutis Biotherapeutics (ARQT) Overvalued in 2026?
Based on GuruFocus' analysis, Arcutis Biotherapeutics stock appears to be undervalued.
The current stock price of $25.02 is trading 18.2% below its estimated GF Value™ of $30.59.
GuruFocus considers Arcutis Biotherapeutics to be Modestly Undervalued.
Key valuation signals for ARQT:
Debt-to-Equity: 0.52 (13% below median its 10-year median of 0.60)
GF Value™: $30.59 vs. price of $25.02 (18.2% below fair value)
Industry Position: 225% above the Biotechnology median (#724 of 958)
No single metric tells the full story. See the ARQT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
56GF Score
Get the complete analysis for ARQT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARQT has been successfully added to your 
